Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial

雷珠单抗生物类似药SB11（Byooviz）与参考产品Lucentis的免疫原性及其与疗效、安全性和药代动力学的关联：一项3期随机临床试验的事后分析